title: Serum insulinlike growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease.
abstract: BACKGROUND
  The level of serum insulinlike growth factor 1 (IGF-1) is increased in idiopathic Parkinson disease (PD).
  
  
  OBJECTIVE
  To assess whether the (1) IGF-1 level is increased in patients with PD at the time of diagnosis, (2) increased IGF-1 level is related to impaired motor function in healthy individuals, and (3) detection of increased IGF-1 level will help to identify persons at risk for PD.
  
  
  METHODS
  Cross-sectional cohort study.
  
  
  METHODS
  Serum IGF-1 was measured in 15 patients with newly diagnosed untreated PD and 139 healthy elderly individuals. Participants at risk for PD (n = 11) were defined as having altered motor function according to the Unified Parkinson's Disease Rating Scale, Part III (UPDRS-III), and dopaminergic dysfunction as indicated by sonographically determined substantia nigra hyperechogenicity.
  
  
  RESULTS
  The IGF-1 level was higher in patients with PD compared with healthy participants (P = .004) and inversely correlated with the UPDRS-III score (ρ = -0.77). The IGF-1 level was not related to motor function in the healthy group. However, there was no significant difference between the IGF-1 level in the at-risk subgroup vs the PD patients (corrected P = .15), and the IGF-1 level was positively correlated with the UPDRS-III score (ρ = 0.80).
  
  
  CONCLUSIONS
  Serum IGF-1 monitoring may be valuable in the diagnosis of PD and for the identification of individuals with a putatively increased risk for PD.
authors: Hertie Institute for Clinical Brain Research, Hoppe-Seyler-Strasse 3, D-72076, Tübingen, Germany. jana.godau@medizin.uni-tuebingen.de
authors: Jana
authors: J
authors: Godau
authors: Katharina
authors: K
authors: Knauel
authors: Karin
authors: K
authors: Weber
authors: Kathrin
authors: K
authors: Brockmann
authors: Walter
authors: W
authors: Maetzler
authors: Gerhard
authors: G
authors: Binder
authors: Daniela
authors: D
authors: Berg
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3; D018969:Insulin-Like Growth Factor Binding Proteins / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000502:physiology; D009460:Neurologic Examination; D010300:Parkinson Disease / Q000097:blood* / Q000175:diagnosis* / Q000503:physiopathology; D011569:Psychiatric Status Rating Scales; D012307:Risk Factors; D017585:Ultrasonography, Doppler, Transcranial / Q000379:methods
chemical_list: C515497:IGFBP3 protein, human; D018972:Insulin-Like Growth Factor Binding Protein 3; D018969:Insulin-Like Growth Factor Binding Proteins; D007334:Insulin-Like Growth Factor I